The TLR3/RIG-I/MDA5 agonist, poly (I: C), has improved long-term survival rates in superficial bladder cancer patients.550 Intratumoral G100, a TLR4 agonist, demonstrated potential benefits in tumor treatment. Here, IFIH1 is linked to neoplasm.